Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.